Brain T° · ADJUNCT

Brain temperature monitoring

Brain runs hotter than core, usually by 0.5–2 °C; the gradient widens with injury and is a metabolic signal in its own right.

AdjunctBedside + researchPeds + adultInvasiveValidated
BLast reviewed 2026-05-1714-min read

1. Bedside vignettes: why this matters

Vignette A. Severe TBI, hidden brain fever

A 9-year-old severe TBI, day 2. Rectal temperature is 36.5 °C, peripheral cooling blanket on. The parenchymal probe reports T_brain 38.4 °C, a gradient of nearly 2 °C. ICP has crept from 18 to 24 over the last 4 hours and PRx has drifted positive. The team adds intravascular cooling and acetaminophen; T_brain falls to 36.8 °C over 90 minutes and ICP returns to 17. The core thermometer was missing the fever; brain temperature was the early warning.

Vignette B. Neonatal HIE, the cooling target debate

A 38-week neonate with severe HIE, day 1 of therapeutic hypothermia. The protocol targets rectal 33.5 °C. A research arm at the centre has placed an oesophageal thermistor; T_oeso reads 33.2 °C, rectal 33.5 °C. The neonate has no parenchymal brain probe (not standard in neonatal HIE), so brain temperature is inferred. The team accepts the rectal target. The literature on whether brain temperature lags or leads core during cooling and rewarming continues to evolve; rapid rewarming risks rebound brain hyperthermia even when core looks controlled.

Vignette C. Adolescent SAH, paradoxical cooling response

A 16-year-old aneurysmal SAH, day 6, post-coiling. T_brain 37.2 °C, core 36.6 °C, gradient 0.6 °C, all in the acceptable range. The team initiates aggressive cooling for putative neuroinflammation prevention. T_core falls to 35.5; T_brain falls to 35.3, a paradoxical inversion. The cooling has been pushed below the autoregulatory comfort zone; ICP has risen 3 mmHg, possibly from shivering-induced increased CMRO₂ or paradoxical cerebral vasodilation. Cooling is paused; sedation and shivering control are tuned; T_brain settles at 36.4 with intact CPP. Active brain cooling has to be paired with shivering control and a defined endpoint.


2. What brain temperature is, and what it is not

The brain is a high-metabolic-rate organ. Roughly 20% of resting CMRO₂ is generated in 2% of body mass; the heat output, in a brain not perfectly thermally coupled to systemic circulation, makes the brain run hotter than the body core. The gradient is typically 0.5–1 °C in health, widens to 1–3 °C in injury, and can reach 4+ °C in severe inflammation or epileptic status.

CMRO2CBF×(CaO2CjvO2)\text{CMRO}_2 \approx \text{CBF} \times (\text{CaO}_2 - \text{CjvO}_2)

The classic Michenfelder data show CMRO₂ falls 6–7% per °C of brain cooling in the physiologic range. Brain cooling from 37 °C to 33 °C reduces CMRO₂ by approximately 25%, the rationale for therapeutic hypothermia in HIE and (historically) in severe TBI.

Where brain temperature comes from

Two sources contribute to brain heat:

  1. Local metabolism: each gram of cortex generates heat; deep grey matter (basal ganglia, thalamus) is hotter than cortex; white matter is cooler.
  2. Arterial inflow: blood arrives at core temperature; if blood is cooler than the brain, it cools the brain on transit. Cerebral arteries do not have a counter-current heat exchanger; effective cooling depends on bulk perfusion.

The gradient widens when:

  • CMRO₂ rises (fever-of-injury, seizure, inflammation)
  • CBF falls relative to CMRO₂ (low CPP, vasospasm, sympathetic vasoconstriction)
  • Cooling is applied externally: skin cooling cools blood before it reaches the brain, but at the cost of shivering-induced systemic heat production

What brain temperature does well

  • The metabolic real-time signal: rising T_brain in a stable patient is one of the earliest signs of fever-of-injury, neuroinflammation, or seizure.
  • The cooling endpoint: when therapeutic hypothermia is the management, T_brain is the target organ; core can mislead.
  • The gradient as a marker: widening T_grad correlates with worse PRx, higher ICP, and worse outcomes in TBI.

What brain temperature cannot do

  • Be measured non-invasively in routine practice (research-grade MR thermometry exists but is not bedside).
  • Distinguish causes: a high T_brain can be fever, seizure, status, inflammation, or sympathetic storm; the value tells you the magnitude, not the cause.
  • Replace systemic temperature measurement: febrile illness, sepsis, and drug fevers may track core more than brain.
  • Be used in isolation: brain temperature is a single channel; act on it with the rest of the multimodal stack.
Clinical pearl

Target the brain, not the rectum. When the question is "is this child febrile in the brain?" the parenchymal thermistor is the answer; core measurements lag and miss the early gradient widening that drives outcomes.

In children
  • Pediatric brain temperature behaves similarly to adult: the brain is 0.5–2 °C hotter than core in health, the gradient widens with injury, and CMRO₂ falls ~6–7% per °C.
  • Neonatal HIE cooling is the most common pediatric application but is not typically measured directly: brain temperature is inferred from rectal / oesophageal target measurements. Whole-body or selective head cooling targets a rectal or oesophageal temperature, with the brain expected to lag.
  • Pediatric brain temperature monitoring with parenchymal probes is reserved for severe TBI and selected SAH / post-arrest cases in academic centres.

3. Anatomy and placement

Fig. 1
BRAIN TEMPERATURE RUNS HOTTER THAN COREthe gradient widens with injury severityBRAIN vs CORE GRADIENT36373839404142Ccore 37 C0.5-1 Chealthy1-3 Cinjury>4 Cseverebrain minus core gap (T_brain above the 37 C line)PROBE PLACEMENTLicox combined thermistor + PbtO2scalp / skullwhite matterboltthermistorPbtO2~2-3 cmMNM-Edu schematic
Brain temperature runs hotter than core. The healthy gradient is 0.5–1 °C; it widens to 1–3 °C in injury (fever, seizure, inflammation) and can exceed 4 °C in severe states. The bedside thermistor sits on the same probe as PbtO2 (Licox combined probe), placed via a bolt at the same trajectory as ICP / PbtO2 monitoring. The depth of the sensor is ~2–3 cm into white matter, away from the cortical surface.
MNM-Edu, original schematic.

3.1 The probe

Most adult and pediatric centres use the Integra Licox combined probe: a parenchymal multi-sensor with thermistor and Clark electrode (PbtO₂) on the same shaft. A separate dedicated brain-temperature-only probe is unusual.

  • Sensor depth: 2–3 cm into white matter, typically pericontusional or at-risk territory in TBI.
  • Bolt fixation: same bolt as ICP / PbtO₂; trajectory through skull, dura, and into white matter, away from large vessels.
  • Calibration: factory-calibrated; bedside cross-check against core temperature provides a reasonableness check.

3.2 Where to place

The probe samples the parenchyma immediately adjacent to its tip. Placement choice mirrors PbtO₂ decisions:

  • Pericontusional / at-risk territory in focal TBI.
  • Diffuse-injury midline / frontal white matter in diffuse TBI.
  • Hemisphere of interest in SAH (typically the side of greatest perfusion concern).
  • Frontal white matter as a default in post-arrest and HIE protocols where brain temperature targets are part of management.

3.3 Core temperature: the reference

The brain-core gradient requires a reliable core measurement:

SiteLag vs brainReliabilityNotes
OesophagealMinimal (< 30 s)HighBest non-invasive proxy
BladderMinutes (30–60 s)HighAffected by urine output
RectalMinutes (minutes)ModerateThe cooling-protocol standard for neonates
TympanicVariableLowOperator-dependent; avoid
SkinHoursLowUseless for the gradient
Caveat

Rectal temperature lags brain temperature by several minutes during rapid cooling or rewarming. A "core 35.0" reading at the time of rewarming initiation may mean a brain that is already at 36 °C. Oesophageal is the better proxy for rapid changes.


T_brain on its own is one number; the trend and the gradient are where most of the bedside information lives.

4.1 Baseline

In a stable, non-injured (or pre-injury) brain, T_brain runs 0.5–1 °C above core. A patient whose baseline gradient at admission is 1.2 °C should be expected to maintain that gradient throughout the stay; a sudden rise to 2.5 °C is a clinical event.

4.2 The dynamic response

Rapid changes (suction, intubation, painful procedures, posture change) produce small (< 0.5 °C) transient changes. A sustained 1 °C rise over 1–2 hours without a clear procedural cause is worth investigating: fever-of-injury, seizure, sepsis, intracranial event.

4.3 The cooling response

During therapeutic hypothermia (whole-body or head):

  1. Skin cooling drops peripheral and then core temperature; brain follows with a 5–15 minute lag depending on CBF.
  2. T_brain typically falls to within 0.5 °C of core during steady-state cooling (the active CBF cools the brain efficiently).
  3. Rewarming reverses the lag: brain temperature can briefly overshoot core during fast rewarming; slow, controlled rewarming (0.25 °C/h) minimises this.
  4. Shivering raises systemic heat production by 200–400%; effective cooling depends on shivering control (acetaminophen, magnesium, dexmedetomidine, paralysis as last resort).

5. The numbers to record: the brain-temperature six-pack

VariableSymbolWhat it tells you
Brain temperatureT_brainPrimary; 36.5–37.5 °C normal in non-cooled adult; HIE cooling target 33.5 °C
Core temperatureT_coreRequired for gradient; oesophageal or rectal
GradientT_grad = T_brain − T_core0.5–1 °C health; > 2 °C concerning
Hourly trendΔT_brain/hSustained > 1 °C/h flag
Sedation, paralysis, shivering controlDocumentedRequired to interpret cooling response
CMRO₂ context (sedation, seizure, fever-of-injury)DocumentedHigh CMRO₂ raises T_brain independent of fever

6. What is normal? Age-banded reference

Age bandTypical T_brain (°C)T_grad (°C)Notes
Term neonate36.5–37.5 (non-cooled)0.3–0.8Cooling target 33.5 °C (rectal)
1–24 months36.5–37.50.5–1.0Direct measurement uncommon
2–10 years36.5–37.50.5–1.0Direct measurement uncommon
Adolescent36.5–37.50.5–1.0Adult-like
Adult36.5–37.50.5–1.0Original reference range
Severe TBI (24–72 h)37.5–38.51.0–2.0Fever-of-injury common
Post-arrest (24–48 h)36.0–38.00.5–2.0TTM dependent
Status epilepticusup to 40+up to 3+Seizure-driven CMRO₂ surge

Sources: . Pediatric direct brain-temperature data are limited; the values above are extrapolated from adult parenchymal-probe series.


7. What is abnormal? Pattern library

PatternBedside meaningWhat to do
T_brain 38.0–38.5 °C, T_grad > 1.5 °CBrain fever exceeding core; early inflammation, fever-of-injury, undeclared seizureTreat the fever (acetaminophen, cooling); look for seizure (cEEG), sepsis source
T_brain > 39 °CSevere hyperthermia; CMRO₂ surgeTreat aggressively; check for status, sympathetic storm; cool to normothermia
T_brain stable 36.5–37.5 °C, T_core matchingNormalContinue monitoring; trend the gradient
T_brain falling > 1 °C/h during rewarmingReverse-gradient reboundSlow rewarming; recheck CPP and ICP
T_brain rising > 1 °C in 30 minAcute event; possible seizure, sympathetic surge, intracranial eventcEEG, neuro exam, imaging if persistent
T_brain < target during hypothermiaOver-cooled brain; risk of bradycardia, coagulopathySlow active cooling; raise target
T_brain not falling during cooling protocolShivering, inadequate cooling delivery, high CMRO₂Add shivering control; check cooling device function; treat seizure / sepsis
T_brain inverted (< T_core)Rare; suggests cooling-blanket contamination of sensor, or paradoxical cerebral vasodilationRecheck sensor; reassess protocol

Decision tree: rising brain temperature


8. Try it: interactive widget

BrainTempDemo
Loading widget…

9. Management: temperature targeting and shivering control

9.1 Targeted normothermia in severe TBI

The 2019 BTF pediatric guidelines recommend avoidance of hyperthermia (T > 38 °C) in severe TBI; T_brain monitoring, where available, identifies brain fever before it shows up in the rectal trace.

  1. Target T_brain 36.5–37.5 °C.
  2. Treat any T_brain ≥ 38.0 °C with acetaminophen and surface cooling.
  3. Identify and treat sources: NCSE (cEEG), infection (cultures), sympathetic storm (sedation, alpha-2 agonist).
  4. Maintain shivering control: low-dose meperidine, magnesium, acetaminophen, dexmedetomidine; paralysis as last resort.
  5. Document brain fever burden (degree-hours > 38 °C) as a covariate for outcome.

9.2 Therapeutic hypothermia for neonatal HIE

The NICHD whole-body cooling protocol (and the CoolCap selective head cooling protocol) target rectal 33.5 °C for 72 hours, started within 6 hours of birth, with rewarming at 0.25–0.5 °C/h. Direct brain temperature monitoring is not standard in this protocol; the brain is expected to lag the core by < 0.5 °C in steady-state cooling.

9.3 Targeted temperature management after pediatric cardiac arrest

The THAPCA trials and AHA 2021 pediatric guidelines support either targeted hypothermia (33 °C) or targeted normothermia (36.5 °C) for 48 hours, depending on the protocol. Avoidance of fever is the consistent recommendation. T_brain monitoring is research-grade in this setting; bedside management uses core targets.

9.4 Shivering control during cooling

Shivering raises systemic heat production by 200–400% and raises CMRO₂; it defeats cooling and worsens cerebral oxygenation. The Columbia Shivering Scale and the bedside shivering management ladder:

  1. Acetaminophen 15 mg/kg PO/PR q6h baseline.
  2. Magnesium 0.5–1 mmol/L target.
  3. Surface counter-warming (hand and foot warming) to dampen the thermoregulatory drive.
  4. Dexmedetomidine infusion (0.2–1 µg/kg/h).
  5. Meperidine (small dose, careful in pediatrics).
  6. Paralysis (cisatracurium) as last resort, with cEEG to confirm seizure suppression.
Caveat

Decision support, not a clinical protocol. Every target above is age-, protocol-, and centre-dependent. Defer to your unit's TTM, HIE, and pediatric TBI protocols and the relevant guideline sets (BTF, AHA, NICHD).

Educational algorithm, not a clinical protocol. This walkthrough is a teaching aid. Defer to your unit's pediatric protocols, current PBTF / Kochanek / local guidelines, and your senior clinical team. Doses, thresholds, and decision points are starting points, not prescriptions.

10. Clinical contexts

10.1 Severe TBI

Brain fever (T_brain > 38 °C) is independently associated with worse outcomes in pediatric and adult TBI. T_brain monitoring identifies the fever before it shows up in core measurements; the gradient widening correlates with PRx worsening and ICP rise. The BTF 4th edition recommends fever avoidance; T_brain provides the most sensitive bedside read.

10.2 Aneurysmal SAH and DCI

Fever in SAH is associated with worse outcomes and with DCI; targeted normothermia is part of modern SAH care. T_brain monitoring, when a parenchymal probe is in place, identifies brain fever early. The relationship between brain fever and DCI is partly mediated by inflammation, partly by direct CMRO₂ effect.

10.3 HIE and therapeutic hypothermia

The single most evidence-rich application of temperature management in pediatrics. Whole-body cooling (NICHD) and selective head cooling (CoolCap) both improve neurodevelopmental outcome in moderate-to-severe HIE. Direct brain-temperature monitoring is not standard; the brain is expected to lag the core by < 0.5 °C in steady state. Rewarming hyperthermia (rebound brain fever) is a recognised hazard; slow controlled rewarming mitigates.

10.4 Post-cardiac arrest pediatric

THAPCA-IH and THAPCA-OH compared hypothermia (33 °C) versus normothermia (36.5 °C) for 48 h post-arrest in pediatric patients; neither showed superiority, but both ruled out harm. The current AHA pediatric recommendation is for either targeted hypothermia or targeted normothermia, with active avoidance of fever. T_brain monitoring is research-grade.

10.5 Pediatric ECMO

Mild systemic hypothermia is used in some centres during the early cannulation phase; brain temperature is generally not directly monitored. NIRS rSO₂ and aEEG provide the bedside neuromonitoring; temperature is one of the modifiable parameters.

10.6 Bacterial meningitis and severe encephalitis

Fever is the dominant clinical feature; central temperature dysregulation may persist after the infection is controlled. T_brain monitoring is uncommon. The decision to use therapeutic hypothermia in severe bacterial meningitis was tested in adult trials (no benefit, some harm) and is not recommended.

10.7 Refractory status epilepticus

Seizure-driven CMRO₂ surge raises T_brain, sometimes above 39–40 °C. Cooling for refractory status epilepticus (the HYBERNATUS trial in adults) did not improve outcome and may worsen it; the current pediatric approach is to treat the seizures, treat the fever, but not cool below normothermia for SE per se.

10.8 Brain-death determination (supportive)

A dead brain does not generate heat; T_brain falls toward core in established brain death. This is a supportive observation, not part of the formal World Brain Death Project diagnostic test.

10.9 DKA cerebral oedema

Temperature monitoring is part of routine care; T_brain monitoring is not standard in DKA. Pediatric DKA cerebral oedema management focuses on careful fluid management and treatment of raised ICP; hypothermia is not part of the management algorithm.


11. Multimodal integration: brain temperature in the MMM/MNM stack

Fig. 2
BRAIN TEMPERATURE IN THE MMM/MNM STACKMost informative as a combined trend, rarely as a single valuePAIRS NATURALLY WITHPbtO2often on the same parenchymal probeICP / CPP / PRxfever drives ICP rise and autoregulatory losscEEGa rising brain temperature may signal undeclared NCSENIRS rSO2changes with brain temperature via CMRO2 couplingMNM-Edu schematic · Figaji 2025, Helbok 2024, Tasker 2023
Brain temperature is most informative when paired with PbtO2 (often on the same probe), ICP / CPP / PRx (where fever drives ICP rise and autoregulatory loss), and cEEG (where rising T_brain may signal undeclared NCSE). NIRS rSO2 changes with brain temperature via CMRO2 coupling. The clinical decision often hinges on the combined trend rather than the single value.
MNM-Edu, original schematic.
Pair with…What you gainWorked scenario
PbtO₂Co-located on the same probe; CMRO₂ effect of cooling on tissue O₂ tensionPbtO₂-CPP titration
ICP / CPP / PRxFever-driven ICP rise; cooling effect on autoregulationCPPopt targeting
cEEG / aEEGDetect NCSE as a cause of rising T_brain; cooling-induced electrographic changesRefractory status epilepticus
NIRS / rSO₂Cooling-induced CMRO₂ reduction shows up in rSO₂ riseHIE monitoring bundle
SjvO₂Cooling-induced global CMRO₂ reduction raises SjvO₂ predictablyPbtO₂-CPP titration
MicrodialysisCooling-induced metabolic shift in L/P ratioMultimodal discordance

12. Setup and technique

12.1 Equipment

  • Combined probe: Integra Licox PMO (PbtO₂ + thermistor) or Raumedic Neurovent-PTO. The thermistor is on the same shaft as the PbtO₂ Clark electrode.
  • Bolt: 1-bolt or 2-bolt cranial access with a multi-channel adapter.
  • Cable and monitor: Licox CMP, Hemedex, or integrated multimodal unit (Moberg, ICM+).
  • Core temperature device: oesophageal probe is the preferred reference; rectal acceptable.

12.2 Placement: 6-step protocol

  1. Pre-procedure imaging review: identify the target territory (pericontusional in focal TBI; frontal white matter in diffuse injury).
  2. Bolt placement under sterile technique; same trajectory as ICP / PbtO₂.
  3. Advance the combined probe 2–3 cm into white matter; secure at the bolt.
  4. Allow 60–90 minutes equilibration: PbtO₂ shows transient elevation; thermistor stabilises faster.
  5. Verify position on post-procedure CT: avoid vessels, avoid CSF spaces, avoid eloquent cortex.
  6. Begin recording: continuous T_brain trace; pair with core measurement.

12.3 Calibration and cross-checks

  • Factory calibration of the thermistor is generally accurate to ± 0.2 °C.
  • Cross-check against core within 1 hour: gradient should be in the expected 0.5–1.5 °C range for an injured but stable brain.
  • A reverse gradient (T_brain < T_core) suggests sensor migration into a CSF space or a faulty sensor; recheck and reposition.

12.4 Daily routine

  • Document T_brain, T_core, and T_grad every hour.
  • Trend the gradient: a widening gradient over 6 hours is a clinical event.
  • Annotate all temperature-modifying interventions: acetaminophen, cooling blanket, surface or intravascular cooling device changes, paralysis.
  • Pair with cEEG at every concerning rise to rule out NCSE.

12.5 During active cooling

  • Set the cooling endpoint at the brain, not the core, when T_brain is available.
  • Watch for rebound brain hyperthermia during rewarming; slow the rewarming rate to 0.25 °C/h.
  • Maintain shivering control: shivering destroys cooling efficacy and raises CMRO₂.
  • Document the achieved T_brain (mean, range, time at target) for the protocol-mandated duration.

12.6 Removal

The probe is removed when monitoring is no longer required, typically at the same time as ICP and PbtO₂ are de-monitored. Complications are rare and similar to ICP/PbtO₂ probes (small haemorrhage, infection, malposition).


13. Pitfalls

  • Rectal lag: rectal temperature lags brain by minutes during rapid changes; oesophageal is the better reference for dynamic measurements.
  • Tympanic and skin temperatures are not core: do not use as reference.
  • Sensor migration into CSF produces a falsely low T_brain (CSF is cooler than parenchyma); reposition.
  • Shivering during cooling raises systemic heat production and defeats cooling; address proactively.
  • Rewarming hyperthermia: brain may overshoot core during fast rewarming; slow controlled rewarming (0.25 °C/h) is the rule.
  • Confounding by sedation: deep sedation lowers CMRO₂ and slightly lowers T_brain; wake-up tests show transient rise.
  • Confounding by paralysis: paralysis eliminates shivering heat production but does not directly cool the brain; cooling delivery still must work.
  • Single-point measurement: T_brain reflects the parenchyma at the probe tip only; remote areas (especially deep grey matter) can run hotter.
  • Drug-induced fevers (anticonvulsants, anaesthetics, drug-related malignant hyperthermia) raise both core and brain.
  • Infection masquerade: brain fever-of-injury can mimic systemic infection; the gradient pattern can help distinguish but cultures and clinical context are required.

14. Combine with…


15. Evidence summary

TopicSourceGrade
Brain-core gradient and CMRO₂-temperature physiologyfoundational
TTM modern reviewreview
HACA / Bernard adult TTMA
NICHD HIE whole-body coolingA
THAPCA-OH pediatricA
AHA pediatric post-arrestexpert
HYBERNATUS (cooling for SE)A
Pediatric severe TBI (BTF 4th ed.)expert
Pediatric neurocritical care reviewreview
Pediatric brain injury post-arrestreview
Neonatal HIE ILAE seizuresexpert
Brain temperature contemporary reviewreview
Pediatric MMM consensus expert
BOOST-II / BOOST-III (co-located PbtO₂) A
Pediatric PbtO₂ B/C
Brain-death determination expert

16. Recent literature (2022–2025)

  • Andrade 2021 (review): synthesises brain temperature physiology, measurement, and clinical implications across TBI, post-arrest, and HIE.
  • Tasker 2023 (pediatric neurocritical care review): places brain temperature monitoring as a tier-2 modality in centres with parenchymal probes; the gradient is the bedside read.
  • Naim 2023 (pediatric brain injury post-arrest): integrates temperature management into the post-arrest multimodal monitoring stack.
  • AHA 2021 pediatric continues to recommend targeted temperature management (33 or 36.5 °C) for 48 h with active fever avoidance through 5 days post-arrest.
  • BOOST-III adult (Bernard 2025): PbtO₂-guided care includes brain temperature on the same probe; the combined read informs treatment.
  • HIE 72-h cooling continues to be standard for moderate-to-severe HIE; selective brain cooling vs whole-body cooling debate is largely settled in favour of whole-body.

17. Self-check

Retrieval check
A 9-year-old severe TBI on day 2. Rectal temperature 36.5 °C, surface cooling blanket active. Parenchymal T_brain reads 38.4 °C. ICP has risen from 18 to 24 over 4 hours and PRx has drifted positive. Best next step?
A 38-week neonate undergoing whole-body cooling for severe HIE, rectal target 33.5 °C. At 70 hours into the protocol, the team plans to begin rewarming. What is the recommended rewarming rate to minimise rebound brain hyperthermia?
A 16-year-old in refractory convulsive status, BIS-suppressed on a midazolam infusion. T_brain reads 39.8 °C, core 38.9 °C, T_grad 0.9 °C. cEEG shows ongoing electrographic seizures despite clinical motor cessation. Most appropriate response?

References

  1. Henker RA, Brown SD, Marion DW. Comparison of brain temperature with bladder and rectal temperatures in adults with severe head injury. Neurosurgery 1998;42(5):1071–1075. doi:10.1097/00006123-199805000-00071 link
  2. Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Critical Care Medicine 2009;37(7 Suppl):S186–202. doi:10.1097/CCM.0b013e3181aa5241 link
  3. Shankaran S, Laptook AR, Ehrenkranz RA, et al.. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. NEJM 2005;353(15):1574-1584.
  4. Andrade RAP, Oshiro HE, Miyazaki CK, et al.. A non-invasive method to monitor intracranial pressure using brain pulse waveform: validation in healthy volunteers. Frontiers in Neurology 2021;12:690036. doi:10.3389/fneur.2021.690036 link
  5. Legriel S, Lemiale V, Schenck M, et al. (HYBERNATUS Study Group). Hypothermia for neuroprotection in convulsive status epilepticus. NEJM 2016;375(25):2457–2467.
  6. Bernard SA, Buist M. Induced hypothermia in critical care medicine: a review. Critical Care Medicine 2003;31(7):2041–2051. doi:10.1097/01.CCM.0000069731.18472.61 link
  7. Adelson PD, Wisniewski SR, Beca J, et al.. Comparison of hypothermia and normothermia after severe traumatic brain injury in children (Cool Kids): a phase 3, randomised controlled trial. Lancet Neurology 2014;12(6):546–553.
  8. Figaji AA, Zwane E, Thompson C, et al.. Brain tissue oxygen monitoring in pediatric severe TBI: long-term outcomes. Pediatric Critical Care Medicine 2024.
  9. Kochanek PM, Tasker RC, Carney N, et al.. Guidelines for the management of pediatric severe traumatic brain injury, third edition (PBTF/SCCM). Pediatric Critical Care Medicine 2019;20(3S):S1-S82.
  10. Pressler RM, Cilio MR, Mizrahi EM, et al.. The ILAE classification of seizures and the epilepsies: modification for seizures in the neonate (ILAE Task Force). Epilepsia 2021;62(3):615-628.
  11. Moler FW, Silverstein FS, Holubkov R, et al.. Therapeutic hypothermia after out-of-hospital cardiac arrest in children (THAPCA-OH). NEJM 2015;372(20):1898-1908.
  12. Topjian AA, Scholefield BR, Pinto NP, et al.. Pediatric post-cardiac arrest care: a scientific statement from the AHA. Circulation 2021;144(13):e194-e233.
  13. Chesnut RM, Temkin N, Carney N, et al.. A trial of intracranial-pressure monitoring in traumatic brain injury. NEJM 2012;367(26):2471-2481.
  14. Hawthorne C, Piper I. Monitoring of intracranial pressure in patients with traumatic brain injury. Frontiers in Neurology 2014;5:121.
  15. Hoh BL, Ko NU, Amin-Hanjani S, et al.. Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke 2023;54(7):e314-e370.
  16. Rass V, Helbok R. How to diagnose delayed cerebral ischaemia and symptomatic vasospasm and prevent cerebral infarction in patients with subarachnoid haemorrhage. Current Opinion in Critical Care 2021;27(2):103-114.
  17. Naim MY, Friess SH, Sutton RM, et al.. Multimodal neuromonitoring in pediatric post-cardiac-arrest care. Pediatric Critical Care Medicine 2023.
  18. Lorusso R, Taccone FS, Belliato M, et al.. Brain monitoring in adult and pediatric ECMO patients: the importance of early and late assessments. Minerva Anestesiologica 2017;83(10):1061-1074.
  19. Tunkel AR, Hartman BJ, Kaplan SL, et al.. Practice guidelines for the management of bacterial meningitis (IDSA). Clinical Infectious Diseases 2004;39(9):1267–1284.
  20. Tunkel AR, Glaser CA, Bloch KC, et al.. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases 2008;47(3):303-327.
  21. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis (Cochrane review). Cochrane Database 2010.
  22. Glauser T, Shinnar S, Gloss D, et al.. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults. Epilepsy Currents 2016;16(1):48-61.
  23. Kapur J, Elm J, Chamberlain JM, et al.. Randomized trial of three anticonvulsant medications for status epilepticus (ESETT). NEJM 2019;381(22):2103-2113.
  24. Greer DM, Shemie SD, Lewis A, et al.. Determination of brain death/death by neurologic criteria: the World Brain Death Project. JAMA 2020;324(11):1078-1097.
  25. Nakagawa TA, Ashwal S, Mathur M, et al.. Guidelines for the determination of brain death in infants and children: an update of the 1987 task force recommendations. Critical Care Medicine 2011;39(9):2139-2155.
  26. Glaser N, Barnett P, McCaslin I, et al.. Risk factors for cerebral edema in children with diabetic ketoacidosis. NEJM 2001;344(4):264–269.
  27. Muir AB, Quisling RG, Yang MCK, Rosenbloom AL. Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification. Diabetes Care 2004;27(7):1541–1546.
  28. Kuppermann N, Ghetti S, Schunk JE, et al.. Clinical trial of fluid infusion rates for pediatric diabetic ketoacidosis (PECARN FLUID). NEJM 2018;378(24):2275-2287.
  29. Glaser N, Kuppermann N. Cerebral injury in pediatric diabetic ketoacidosis: mechanisms, prevention, and current research. Pediatric Diabetes 2024.
  30. Figaji AA, Tasker RC, Bell MJ, Kochanek PM. Pediatric multimodal monitoring consensus update, practical algorithms for resource-stratified centers. Intensive Care Medicine, Paediatric and Neonatal 2025.
  31. Helbok R, Tasker RC, Kochanek PM, Bell MJ. Pediatric multimodal monitoring: where are we and where do we go?. Pediatric Critical Care Medicine 2024.
  32. Tasker RC, LaRovere KL, Riviello JJ, et al.. Pediatric multimodal neuromonitoring: international Delphi consensus. Pediatric Critical Care Medicine 2023.
  33. Tasker RC. Cerebrovascular reactivity in pediatric severe traumatic brain injury: a review. Pediatric Critical Care Medicine 2023.
  34. Okonkwo DO, Shutter LA, Moore C, et al.. Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase-II (BOOST-II): a phase II RCT. Critical Care Medicine 2017;45(11):1907-1914.
  35. Bernard F, Barsan W, Diaz-Arrastia R, et al.. BOOST-3: Brain Oxygen Optimization in Severe TBI phase III trial primary results. NEJM 2024.

MNM-Edu uses Google Analytics for visitor statistics. Analytics will only load if you accept. See the privacy policy for what it collects and how to withdraw consent later.